Fang Hu1, Changhui Li1, Jianlin Xu1, Jindong Guo2, Yinchen Shen1, Wei Nie1, Xiaoxuan Zheng1, Lixin Wang3, Hai Zhang1, Baohui Han4, Xueyan Zhang5. 1. Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, PR China. 2. Department of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, PR China. 3. Integrated TCM & Western Medicine Department, Shanghai Pulmonary Hospital Affiliated to Tongji University, PR China. 4. Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, PR China. Electronic address: 18930858216@163.com. 5. Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, PR China. Electronic address: zxychest@163.com.
Abstract
OBJECTIVES: Whether epidermal growth factor receptor tyrosine-kinase inhibitors (EGFR-TKIs) plus local consolidative therapy (LCT) has survival benefit over EGFR-TKIs alone in lung adenocarcinoma patients with EGFR mutation and bone oligometastases remains controversial. MATERIALS AND METHODS: We conducted a retrospective study to assess the effects of LCT in lung adenocarcinoma patients with bone oligometastases and EGFR mutation. The primary endpoint was overall survival (OS); the secondary endpoints was progression-free survival (PFS). RESULTS: A total of 127 lung adenocarcinoma patients with EGFR mutation and bone oligometastases were assessed, including 65 patients received EGFR-TKIs alone (monotherapy group) and 62 patients received EGFR-TKIs plus local consolidative therapy (LCT) (combination group). Addition of LCT was associated with significantly longer OS (36.3 vs. 21.0 months, P = 0.01; hazard ratio [HR] = 0.537, 95% confidence interval [CI]: 0.360-0.801, p = 0.01) and PFS (14.0 vs. 8.1 months, P = 0.01; HR = 0.613, 95%CI: 0.427-0.879, p = 0.01) in the whole cohort. CONCLUSION: In lung adenocarcinoma patients with EGFR-mutation and bone oligometastases, LCT plus EGFR-TKIs therapy is associated with significantly longer OS and PFS compared with EGFR-TKIs therapy alone, indicating that LCT plus EGFR-TKIs therapy might be a better therapeutic option for this patient population.
OBJECTIVES: Whether epidermal growth factor receptor tyrosine-kinase inhibitors (EGFR-TKIs) plus local consolidative therapy (LCT) has survival benefit over EGFR-TKIs alone in lung adenocarcinomapatients with EGFR mutation and bone oligometastases remains controversial. MATERIALS AND METHODS: We conducted a retrospective study to assess the effects of LCT in lung adenocarcinomapatients with bone oligometastases and EGFR mutation. The primary endpoint was overall survival (OS); the secondary endpoints was progression-free survival (PFS). RESULTS: A total of 127 lung adenocarcinomapatients with EGFR mutation and bone oligometastases were assessed, including 65 patients received EGFR-TKIs alone (monotherapy group) and 62 patients received EGFR-TKIs plus local consolidative therapy (LCT) (combination group). Addition of LCT was associated with significantly longer OS (36.3 vs. 21.0 months, P = 0.01; hazard ratio [HR] = 0.537, 95% confidence interval [CI]: 0.360-0.801, p = 0.01) and PFS (14.0 vs. 8.1 months, P = 0.01; HR = 0.613, 95%CI: 0.427-0.879, p = 0.01) in the whole cohort. CONCLUSION: In lung adenocarcinomapatients with EGFR-mutation and bone oligometastases, LCT plus EGFR-TKIs therapy is associated with significantly longer OS and PFS compared with EGFR-TKIs therapy alone, indicating that LCT plus EGFR-TKIs therapy might be a better therapeutic option for this patient population.
Authors: Vincent Fallet; Lise Matton; Antoine Schernberg; Anthony Canellas; François H Cornelis; Jacques Cadranel Journal: Transl Lung Cancer Res Date: 2021-07
Authors: Yuxiang Wang; Wenjuan Yu; Jian Shi; Rong Qiu; Nan Jiang; Zhuofan Wang; Jie Yang; Zhongfei Jia; Meng Song Journal: Technol Cancer Res Treat Date: 2022 Jan-Dec